港股异动丨康希诺生物大涨逾11% 股价再创上市以来新高
格隆汇2月14日丨康希诺生物(6185.HK)大涨
逾
11%,报83.45港元,今年以来股价已近累涨逾40%,且刷新历史新高,总市值186亿港元。

康希诺生物近日公告称,其科创板上市申请已获得上交所受理。此次申请上市,康希诺拟申请公开发行不超过2480万股,拟募集资金10亿元,将用于生产基地二期建设、在研疫苗研发、疫苗追溯、冷链物流体系及信息系统建设以及补充流动资金之中。
此外,2月10日,中国疫苗行业协会官方微信发布消息称,截至目前有18家会员单位正在开展新冠肺炎疫苗的研制工作,康希诺生物亦位列其中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.